CHD sector forecast to reach $19.4B by 2017 in seven leading markets
The new Pharmacor report from Decision Resources, entitled Coronary Heart Disease finds that the market to treat the disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in seven leading markets - the USA, France, Germany, Italy, Spain, the UK and Japan. Growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Efient/Effient (prasugrel), AstraZeneca's Brilinta (previously known as AZD6140), and Schering-Plough's SCH-530348, as well as the introduction of two new cholesterol ester transfer protein inhibitors from Roche/Japan Tobacco and Merck & Co.
Despite the patent expiry of the two sales-leading CHD therapies by 2012 - Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover (clopidogrel) and Pfizer's Lipitor (atorvastatin - the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix (fenofibrate), Solvay's Lipanthyl (fenofibrate) and Abbott's Niaspan (niacin) will also offset the negative impact of generic erosion, according to the report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze